Chardan Capital Sticks to Their Buy Rating for Alnylam Pharma

By Jason Carr

In a report released today, Madhu Kumar from Chardan Capital reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $110. The company’s shares opened today at $65.

According to, Kumar is a 1-star analyst with an average return of -4.6% and a 51.4% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Crispr Therapeutics AG, and Intellia Therapeutics.

Currently, the analyst consensus on Alnylam Pharma is Strong Buy and the average price target is $82.43, representing a 26.8% upside.

In a report issued on May 5, Needham also reiterated a Buy rating on the stock with a $68 price target.

The company has a one year high of $80.11 and a one year low of $31.38. Currently, Alnylam Pharma has an average volume of 874.3K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALNY in relation to earlier this year. Most recently, in January 2017, John Maraganore, the CEO of ALNY bought 1,340 shares for a total of $25,004.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.